Medicinal Chemistry of Kinase Inhibitors: A Review of Recent Advances

Shinymol[1], Pushpendra Kuumar[2]*, Sakshi Singh[3], Manoj Kashyap[4], Shivam Kumar[2], Shraddha Sunil Ambhore[5], Neethu Asokan[6], Rekha Rani[7]

[1]Assistant Professor, Smt. Manjira Devi University, Rukmani Nagar, Hitanu Dhanari, Dunda, Uttarkashi, Hitaru, Uttarakhand 249151.

[2]Faculty of Pharmacy, Maharaja Agrasen Himalayan Garhwal University, Pauri Garhwal, Uttarakhand, India, 246169.

[3] Faculty of Pharmacy, IFTM University Moradabad, 244102, India.

[4]Assistant Professor, Pharmaceutical Chemistry, School of Pharmacy, Pragjyotishpur University, Hajongbari, Chadrapur, Guwahati, Assam 781150, India

[5]Suyash college of pharmacy Warud Bk dist. Jalna TQ. Jafrabad Maharashtra, India.

[6]Sri Sathya Sai University for Human Excellence, Kalaburagi, Karnataka, India 565313

[7] School of Pharmacy, ITM University, Gwalior, 475001, Madhya Pradesh.

***Corresponding Author:**

Mr Pushpendra Kuumar, pusp92744@gmail.com

Shivam Kumar, shivam31d99@gmail.com

Abstract

Kinase inhibitors have emerged as pivotal therapeutic agents due to their ability to target and modulate the activity of kinases, enzymes that regulate crucial cellular processes through phosphorylation. Dysregulated kinase activity is implicated in various diseases, particularly cancer, making kinase inhibitors an essential class of drugs in modern medicine. This review highlights recent advances in the medicinal chemistry of kinase inhibitors, focusing on their mechanisms of action, development, and optimization for therapeutic applications. We discuss the evolution from first-generation ATP-competitive inhibitors to next-generation drugs with enhanced selectivity, potency, and pharmacokinetic profiles. The article also covers the challenges in overcoming resistance, minimizing off-target effects, and improving drug delivery. Finally, we explore emerging strategies, including dual-specificity inhibitors, combination therapies, and the growing field of personalized medicine. As research continues, the design of novel kinase inhibitors promises to offer more effective treatments with fewer side effects, particularly in cancer and autoimmune diseases, paving the way for a new era in targeted therapy. This review would focus on detailing these advancements, including new molecular insights, design strategies, and clinical findings that have shaped the landscape of kinase inhibitor drugs.

Keywords: Kinase inhibitors, medicinal chemistry, targeted therapy, cancer treatment, ATP-competitive inhibitors, allosteric inhibitors.

Introduction

Overview of kinase biology: Kinases play a crucial role in signal transduction pathways that regulate cellular processes such as growth, differentiation, metabolism, and apoptosis.

Importance of kinase inhibitors in disease treatment: Dysregulation of kinases can lead to diseases like cancer, autoimmune disorders, and inflammatory diseases [1-3].

Mechanism of Action of Kinase Inhibitors

ATP-Competitive Inhibitors: These inhibitors predominantly target the ATP-binding pocket of kinases, competing with ATP and thereby preventing substrate phosphorylation. Due to the conserved nature of the ATP-binding site among kinases, selectivity can be challenging, but these inhibitors are widely studied and have been clinically successful [4-6].

Allosteric Inhibitors: Unlike ATP-competitive inhibitors, allosteric inhibitors bind to regulatory sites distinct from the ATP-binding pocket. This binding induces conformational changes in the kinase, reducing its activity and often improving selectivity by targeting unique structural features [6-8].

Irreversible Inhibitors: These inhibitors form covalent bonds with specific residues, typically a reactive cysteine in the kinase. The covalent interaction results in prolonged inhibition, which can be beneficial for sustained therapeutic effects. However, this irreversible mechanism requires careful consideration to avoid off-target effects and potential toxicity. [9-10].

Types of Kinase Inhibitors

Small Molecule Kinase Inhibitors: These inhibitors are among the most widely used in targeted cancer therapies. They function by binding either to the active site (ATP-binding pocket) or to allosteric sites on kinases, thereby preventing kinase activation and subsequent signaling pathways involved in cell proliferation and survival. Depending on their binding mechanism, these inhibitors can be ATP-competitive or non-competitive [11]. Prominent examples include:

- **Imatinib:** A first-generation ATP-competitive inhibitor that targets the BCR-ABL fusion protein, which is a hallmark of chronic myeloid leukemia (CML). By blocking ATP binding, imatinib effectively halts the abnormal kinase activity driving cancer cell growth [12].
- **Erlotinib:** A selective inhibitor of epidermal growth factor receptor (EGFR). It binds to the ATP-binding pocket of EGFR, blocking downstream signalling pathways that promote cell proliferation, making it effective in treating non-small cell lung cancer (NSCLC).

Small molecule inhibitors have been a major breakthrough in personalized medicine, enabling the targeting of specific oncogenic drivers with improved efficacy and reduced off-target effects compared to traditional chemotherapies [13].

- **Monoclonal Antibodies:** Monoclonal antibodies are large, biologic molecules that target the extracellular domains of receptor kinases, preventing ligand binding and

downstream signalling [14]. These antibodies offer high specificity and prolonged therapeutic effects due to their ability to engage the immune system. A notable example is trastuzumab, an anti-HER2 monoclonal antibody used in the treatment of HER2-positive breast cancer. By binding to the extracellular domain of the HER2 receptor, trastuzumab blocks receptor activation and promotes immune-mediated destruction of cancer cells. This targeted approach has significantly improved outcomes in patients with HER2-overexpressing tumors [15-16].

- **Targeted Protein Degradation (TPD) Approaches:** Unlike traditional inhibitors that block kinase activity, TPD strategies focus on eliminating the target kinase altogether by leveraging the cell's natural protein degradation machinery [17]. One of the most prominent approaches is PROTACs (Proteolysis-Targeting Chimeras), which are bifunctional molecules designed to recruit the target protein to the ubiquitin-proteasome system, leading to its degradation [18].
- PROTACs consist of two functional domains:
- A ligand that binds to the target kinase.
- An E3 ligase recruiter that brings the kinase into proximity with an E3 ubiquitin ligase, marking it for proteasomal degradation.
- This approach has the potential to overcome resistance mechanisms seen with traditional kinase inhibitors by eliminating the kinase rather than merely inhibiting its activity. PROTAC-based degraders are being developed for several kinases, including BTK and HER2, with some currently in clinical trials [19].



Fig1: Different types of inhibitors

Challenges in Developing Kinase Inhibitors

Selectivity and Off-Target Effects: Kinases share structural similarities, making selectivity challenging. Off-target effects can cause adverse side effects. Resistance Mechanisms: Similar to antibiotics and antiviral drugs, kinase inhibitors face issues with resistance, such as mutations in the kinase target or activation of bypass signaling pathways [20-22]. The development of kinase inhibitors has revolutionized targeted cancer therapies. However, several challenges remain that limit their efficacy and broader clinical application:

1. Selectivity and Off-Target Effects

Kinases share a highly conserved ATP-binding pocket, making it difficult to develop inhibitors with high selectivity for a specific kinase. Lack of selectivity can result in off-target effects,

leading to toxicity and adverse side effects in patients. Achieving a balance between potency and selectivity remains a key challenge in kinase inhibitor design [23-26].

2. Drug Resistance

Resistance to kinase inhibitors is a significant clinical problem. Tumors can develop mutations in the target kinase that reduce the binding affinity of the inhibitor, rendering the drug ineffective. Additionally, bypass signaling pathways may be activated, allowing cancer cells to maintain growth and survival despite kinase inhibition. For example, mutations in the EGFR and BCR-ABL genes are well-documented causes of resistance to erlotinib and imatinib, respectively [27].

3. Pharmacokinetics and Bioavailability

Developing kinase inhibitors with optimal pharmacokinetic properties is challenging. Many kinase inhibitors have poor solubility, oral bioavailability, or short half-lives, which can reduce their therapeutic efficacy. Ensuring that the drug reaches the target tissue at sufficient concentrations while minimizing systemic exposure remains a key consideration [28].

4. Toxicity and Adverse Effects

Kinase inhibitors often target kinases that are also involved in normal cellular processes, leading to on-target toxicity. Common side effects include cardiotoxicity, skin reactions, diarrhea, and liver toxicity. For example, cardiotoxicity is a well-known side effect of HER2 inhibitors like trastuzumab [29].

5. Targeting Allosteric Sites

While ATP-competitive inhibitors are the most common, targeting allosteric sites is a promising approach to achieve better selectivity. However, identifying suitable allosteric sites and developing inhibitors that bind effectively to these sites is technically challenging [30].

6. Irreversible Inhibitors and Covalent Bonding

Irreversible inhibitors form covalent bonds with kinases, providing prolonged inhibition. However, designing irreversible inhibitors that are both effective and safe is difficult, as covalent bonding can increase the risk of off-target effects and toxicity [31].

7. Tumor Heterogeneity

Cancer cells within the same tumor can exhibit genetic heterogeneity, making it difficult for a single kinase inhibitor to be effective against all cancer cell populations. This heterogeneity often requires **combination therapies** to target multiple pathways simultaneously [32].

8. Cost and Development Time

The development of kinase inhibitors is expensive and time-consuming. Identifying and optimizing a lead compound, conducting preclinical studies, and completing clinical trials can

take several years and require significant financial investment. Additionally, regulatory hurdles further complicate the process [33].

Pharmacokinetics and Toxicity: The bioavailability, metabolic stability, and toxicity profiles of kinase inhibitors are critical for their success in clinical settings. Pharmacokinetics and toxicity are critical considerations in the development and clinical use of kinase inhibitors. These factors significantly impact the efficacy, safety, and dosing strategies for these drugs [34].



Fig 2: Pharmacokinetics and Toxicity

1. Pharmacokinetics (PK)

Pharmacokinetics refers to the absorption, distribution, metabolism, and excretion (ADME) of kinase inhibitors. Optimizing these parameters is essential to achieve therapeutic drug levels at the target site while minimizing side effects.

- **Absorption:** Many kinase inhibitors are administered orally, and their absorption can be influenced by factors such as solubility, food intake, and gastrointestinal conditions. For example, some inhibitors require specific formulations to enhance bioavailability.
- **Distribution:** Kinase inhibitors must efficiently reach their target tissues. However, their lipophilicity and binding to plasma proteins can impact their distribution.
- **Metabolism:** Most kinase inhibitors are metabolized by the cytochrome P450 (CYP) enzyme system, particularly CYP3A4. This can lead to drug-drug interactions, especially with other medications that are also metabolized by CYP enzymes.
- **Excretion:** Kinase inhibitors are typically excreted via the **hepatic or renal pathways**. Impaired liver or kidney function can alter the drug's clearance, necessitating dose adjustments [35-38].

2. Toxicity

Kinase inhibitors can cause both on-target and off-target toxicity, which pose significant challenges in their clinical use.

- **On-Target Toxicity:** This occurs when the inhibition of the intended kinase disrupts normal physiological functions. For instance, EGFR inhibitors like erlotinib can cause skin rash and diarrhea, as EGFR is also expressed in healthy tissues.
- **Off-Target Toxicity:** Due to the high structural similarity among kinases, many inhibitors can inadvertently target unintended kinases, leading to unwanted side effects. For example, cardiotoxicity is a well-known adverse effect associated with some tyrosine kinase inhibitors (TKIs) like imatinib and lapatinib [39].
- **Hepatotoxicity:** Liver toxicity is a common concern, as many kinase inhibitors are metabolized in the liver. Elevated liver enzymes, jaundice, and, in severe cases, drug-induced liver injury (DILI) have been reported.
- **Cardiotoxicity:** Inhibition of kinases involved in cardiac function, such as VEGFR, can lead to hypertension, QT interval prolongation, and heart failure. HER2-targeting drugs like trastuzumab are associated with reduced left ventricular ejection fraction (LVEF) and cardiomyopathy [40].
- **Gastrointestinal Toxicity:** Kinase inhibitors, especially those targeting EGFR, can cause diarrhea, nausea, and vomiting, affecting patient compliance and quality of life [41].

3. Strategies to Mitigate Toxicity

To minimize toxicity while maintaining efficacy, various strategies are employed:

- **Dose Optimization:** Adjusting the dose based on the patient's response and tolerability.
- **Combination Therapy:** Using lower doses of multiple inhibitors to reduce toxicity.
- **Designing More Selective Inhibitors:** Developing allosteric inhibitors and PROTACs to achieve higher selectivity.
- **Monitoring and Managing Side Effects:** Regular monitoring of liver and cardiac function and providing supportive care for side effects like skin rash and diarrhea [42-43].

Recent Advances in Kinase Inhibitor Design

The design and development of kinase inhibitors have seen remarkable progress over the last decade. Researchers have made significant strides in overcoming challenges related to selectivity, resistance, and toxicity, leading to the emergence of novel approaches and therapies. Below are some key advances in kinase inhibitor design:

1. Allosteric Inhibitors and Non-ATP-Competitive Inhibitors

While traditional kinase inhibitors are ATP-competitive, targeting the ATP-binding pocket, there has been growing interest in allosteric inhibitors that bind to sites outside of the ATP-binding region [44-45]. These inhibitors can induce conformational changes that reduce kinase activity or promote a closed, inactive state, offering several advantages:

- Improved selectivity due to the targeting of unique, non-conserved sites on kinases.
- Reduced likelihood of cross-reactivity with other kinases, minimizing off-target toxicity.
  For example, palbociclib, an allosteric inhibitor, selectively inhibits cyclin-dependent kinases (CDK4/6), and has shown efficacy in treating breast cancer [46].

2. PROTACs (Proteolysis-Targeting Chimeras)

PROTACs have emerged as a novel approach to targeted protein degradation. These bifunctional molecules link a target protein to an E3 ligase, leading to the recruitment of the protein to the proteasome for degradation rather than merely inhibiting its activity. PROTACs offer:

- The ability to degrade kinases that are difficult to inhibit by traditional means.
- The potential to target undruggable kinases by exploiting their unique structural features.
  A promising PROTAC-based drug targeting BTK (Bruton's tyrosine kinase) has shown success in preclinical trials [47].

3. Covalent Inhibitors

Covalent inhibitors form irreversible bonds with specific cysteine residues in the kinase active site, offering prolonged inhibition. Recent advances have focused on enhancing the selectivity and safety of these inhibitors, as non-selective binding could lead to off-target toxicity. For instance, ibrutinib, an irreversible inhibitor of BTK, has shown clinical success in treating B-cell malignancies, while minimizing resistance and providing long-lasting therapeutic effects [48].

4. Kinase Inhibitor Combinations

The complexity of cancer signaling pathways has made it increasingly clear that single-agent therapies are often not sufficient. Recent efforts have focused on combination therapies using multiple kinase inhibitors or combining kinase inhibitors with other classes of drugs, such as immune checkpoint inhibitors or chemotherapy agents. These combinations aim to:

- Overcome drug resistance by targeting multiple pathways simultaneously.
- Enhance therapeutic efficacy while minimizing toxicity.
- For example, combining EGFR inhibitors with HER2-targeted therapies has shown efficacy in non-small cell lung cancer (NSCLC) [49].

5. Targeting Kinase Isoforms and Mutants

Another significant advance in kinase inhibitor design is the ability to selectively target kinase isoforms and mutant forms of kinases that drive disease. For instance, targeting the T790M mutation in EGFR with second-generation EGFR inhibitors, such as osimertinib, has shown significant clinical benefits in patients with resistant mutations in NSCLC. Similarly, inhibitors designed for specific BCR-ABL mutations have been developed for chronic myelogenous leukemia (CML).

6. Structure-Based Design and Artificial Intelligence

The use of structure-based drug design (SBDD) has greatly advanced in the last decade, aided by the availability of high-resolution crystal structures and computational tools. Additionally, the application of artificial intelligence (AI) and machine learning (ML) in drug discovery has enabled faster identification of potential kinase inhibitors by predicting binding affinities and selectivity profiles [50]. These methods help in:

- Designing inhibitors that are more specific and potent.
- Reducing the time and cost of drug development.

7. Targeting the Kinome with Small-Molecule and Peptide-Based Inhibitors

Research has also focused on targeting the entire kinome (the full set of kinases in a cell) using small-molecule inhibitors and peptide-based inhibitors. These approaches aim to inhibit multiple kinases within a pathway, offering a broader therapeutic effect while reducing the risk

of resistance development. Kinase inhibitors targeting MAPK, PI3K/Akt, and JAK-STAT pathways are examples of these therapeutic strategies in clinical trials [51].

- **Structure-Based Drug Design (SBDD):** Advances in X-ray crystallography and cryo-EM have allowed for better understanding of kinase structures, facilitating the design of more selective and potent inhibitors.
- **Dual-Specificity Inhibitors:** Development of inhibitors that target multiple kinases simultaneously, offering more comprehensive therapeutic effects, especially in cancers with complex signaling pathways.
- **Nanotechnology in Drug Delivery:** Using nanomaterials to improve the bioavailability and targeted delivery of kinase inhibitors [52-53].

Clinical Applications

Kinase inhibitors have found widespread use in the treatment of a variety of diseases, particularly cancers and autoimmune disorders. Ongoing research is also exploring their potential in neurodegenerative diseases [54].

1. Cancer Therapy

Kinase inhibitors have revolutionized cancer therapy by targeting specific kinases involved in tumor growth and survival. These inhibitors can block key signaling pathways that promote cancer cell proliferation, angiogenesis, and metastasis. Some key targets in cancer therapy include:

- Epidermal Growth Factor Receptor (EGFR): EGFR inhibitors, such as erlotinib and gefitinib, are used in treating non-small cell lung cancer (NSCLC) and other solid tumors. These inhibitors block EGFR signaling, which is often upregulated in cancers [55].
- Vascular Endothelial Growth Factor Receptor (VEGFR): VEGFR inhibitors like sunitinib and bevacizumab are used to inhibit angiogenesis, the process by which tumors form new blood vessels. These drugs are effective in treating cancers like renal cell carcinoma and colorectal cancer [56].
- BRAF Mutations: In cancers with BRAF V600E mutations, such as melanoma, dabrafenib and vemurafenib are used to specifically inhibit the BRAF kinase, which is hyperactivated in these tumors [57].

2. Autoimmune Diseases

Kinase inhibitors, particularly those targeting Janus kinases (JAKs), have proven effective in treating autoimmune diseases by modulating the immune response. These inhibitors block the JAK-STAT signaling pathway, which is involved in immune cell activation and inflammation. Key examples include:

- Rheumatoid Arthritis (RA): Tofacitinib and baricitinib, both JAK inhibitors, are FDA-approved for treating RA by reducing inflammation and preventing joint damage [58].
- Inflammatory Bowel Disease (IBD): Tofacitinib has also been approved for the treatment of ulcerative colitis, one of the major forms of IBD, by targeting JAK1 and JAK3 [59].

3. Neurodegenerative Diseases

While kinase inhibitors have mainly been explored for cancer and autoimmune diseases, there is growing interest in their potential in treating neurodegenerative diseases like Alzheimer's disease and Parkinson's disease. Kinases involved in neuroinflammation, neuroprotection, and cell signaling are being targeted to slow disease progression [60]. Some key areas of research include:

- GSK3β Inhibitors: Glycogen synthase kinase 3 beta (GSK3β) plays a role in the pathogenesis of Alzheimer's disease, and inhibitors targeting this kinase are under investigation to reduce tau phosphorylation and amyloid plaque formation, which are characteristic features of Alzheimer's [61].
- CDK5 Inhibitors: Cyclin-dependent kinase 5 (CDK5) is another kinase implicated in neurodegenerative diseases. CDK5 inhibitors are being studied for their potential to prevent neurotoxicity and neuronal loss in conditions like Parkinson's disease and Alzheimer's [62].

Future Directions in Kinase Inhibitor Development

The future of kinase inhibitor therapy holds significant promise, with several exciting advancements on the horizon. These include the integration of precision medicine, exploration of combination therapies, and the development of next-generation kinase inhibitors [63].



Fig 3: Future Directions in Kinase Inhibitors Development

1. Precision Medicine

Precision medicine involves tailoring medical treatment to the individual characteristics of each patient, particularly their genetic and molecular profiles. In the context of kinase inhibitors, this approach has the potential to:

- Identify specific mutations or molecular alterations that drive cancer or other diseases, allowing for the selection of the most effective kinase inhibitor for each patient.
- Minimize side effects by targeting only the relevant kinases or pathways, thus reducing off-target effects and improving patient outcomes.
- For example, genetic screening can identify patients with specific mutations in EGFR, BRAF, or ALK, enabling the use of the most appropriate targeted therapies. Similarly, in autoimmune diseases, identifying specific JAK mutations could guide the use of JAK inhibitors to enhance efficacy and reduce adverse effects [64-65].

2. Kinase Inhibitors in Combination Therapies

The complexity of disease mechanisms, particularly cancer, has highlighted the need for combination therapies. By combining kinase inhibitors with other treatments, such as chemotherapy, immunotherapy, or other targeted therapies, the therapeutic efficacy can be greatly enhanced while overcoming resistance [66]. Some potential combination strategies include:

- **Combination with chemotherapy:** Combining kinase inhibitors with traditional chemotherapy agents can enhance the cytotoxic effects, especially in cancers resistant to single-agent therapies.
- **Combination with immunotherapy:** Immune checkpoint inhibitors can be combined with kinase inhibitors to activate immune responses against tumors. For example, combining VEGF inhibitors with immune checkpoint inhibitors has shown promising results in various cancers.
- **Combination with targeted therapies:** Using kinase inhibitors alongside other targeted drugs can overcome drug resistance by targeting multiple pathways simultaneously. For instance, combining BRAF inhibitors with MEK inhibitors in melanoma has improved patient outcomes [67-69].

3. Next-Generation Kinase Inhibitors

As the understanding of kinase biology evolves, so too does the development of next-generation kinase inhibitors. These newer drugs are being designed to:

- **Enhance selectivity:** By targeting more specific kinase isoforms or mutants, these inhibitors aim to reduce off-target effects and minimize toxicity. Advances in structure-based drug design and crystallography allow for the development of highly selective inhibitors.
- **Overcome resistance:** New inhibitors are being designed to bypass mechanisms of resistance that limit the effectiveness of current kinase inhibitors. For example, allosteric inhibitors that bind to regions outside the ATP-binding site have the potential to evade resistance mutations that affect the ATP-binding pocket.
- **Improve pharmacokinetics:** Next-generation inhibitors are being optimized for better absorption, longer half-lives, and reduced side effects, enhancing their clinical utility. Covalent inhibitors and PROTACs represent innovative approaches to achieving prolonged inhibition and targeted degradation of specific kinases [70-72].

Conclusion

The recent advances in kinase inhibitor development have significantly enhanced therapeutic options, particularly in oncology, where these inhibitors have proven to be instrumental in targeting specific kinases involved in tumor growth. This targeted approach not only offers improved precision compared to traditional therapies but also has the potential to minimize side effects by selectively inhibiting disease-driving pathways. Beyond oncology, kinase inhibitors are also showing promise in treating autoimmune diseases and neurodegenerative disorders, broadening their clinical applications. Despite their successes, challenges remain in fully optimizing kinase inhibitors. The development of drug resistance is a significant concern, with tumors and diseases evolving mechanisms to evade inhibition. This highlights the need for ongoing innovation in treatment strategies, such as combining kinase inhibitors with other

therapies to overcome resistance and increase efficacy. Additionally, there is a need for more selective inhibitors to reduce off-target effects, which can lead to toxicity, particularly with long-term use. The emergence of combination therapies, next-generation inhibitors, and precision medicine offers significant promise for addressing these challenges. By leveraging detailed molecular profiles of patients, precision medicine can help identify the most suitable kinase inhibitors, minimizing adverse effects and maximizing therapeutic benefit. Next-generation kinase inhibitors, with their enhanced selectivity and better pharmacokinetic profiles, aim to address the limitations of current drugs, reducing side effects while improving treatment outcomes. Furthermore, ongoing research into allosteric inhibitors, targeted protein degradation, and combination regimens promises to expand the therapeutic potential of kinase inhibitors. As our understanding of kinase biology deepens, these innovations will continue to enhance the efficacy, safety, and applicability of kinase inhibitors, making them an even more integral component of modern medicine. In summary, while kinase inhibitors have already transformed the treatment landscape, particularly in oncology, ongoing research and development efforts will further refine their use. As the field progresses, we can anticipate even more powerful and personalized treatment options for a variety of diseases, marking a new era in therapeutic innovation.

References

1. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. The protein kinase complements of the human genome. Science, 2002, *298*(5600), 1912-1934.
2. Cohen, P. Protein kinases—the major drug targets of the twenty-first century? Nature Reviews Drug Discovery, 2002, 1(4), 309-315.
3. Johnson, T. O., & Ghosh, S. Kinase inhibitors in cancer therapy: From molecular targets to clinical outcomes. Journal of Clinical Oncology, 2016, 34(4), 230-239.
4. Zhao, Y., & Guan, K. L**.** The PKD family of protein kinases. Genes & Development, 2011, 25(5), 492-505.
5. Deininger, M. W., & Druker, B. J. Specific targeted therapy of chronic myelogenous leukaemia with imatinib. Pharmacological Reviews, 2003, *55*(3), 401-423.
6. Baker, S. J., & Reddy, S. M. Targeted therapies in cancer: Kinase inhibitors and the road to personalized treatment. Journal of Clinical Medicine, 2014, 3(1), 85-99.
7. Yu, H., & Jove, R. The STATs of cancer—new molecular targets come of age. Nature Reviews Cancer, 2004, 4(2), 97-105.

8. Tsuji, D., & Nakagawa, Y. Targeting immune kinases in cancer immunotherapy. Nature Reviews Cancer, 2019 19(6), 345-365.
9. Nesbit, M. A., & Atwell, S. Advances in kinase inhibitor development for cancer therapy. Future Medicinal Chemistry, 2015, 7(9), 1115-1131.
10. Selleck, S. B., & Ward, P. Therapeutic kinase inhibitors: Current progress in clinical trials. Journal of Medicinal Chemistry, 2016, 59(14), 6606-6632.
11. Blume-Jensen, P., & Hunter, T. (2001). Oncogenic kinase signalling. **Nature**, 411(6835), 355-365.
12. Cohen, P. Protein kinases the major drug targets of the twenty-first century? Nature Reviews Drug Discovery, 2002,1(4), 309-315.
13. Wu, P., Nielsen, T. E., & Clausen, M. H. Small-molecule kinase inhibitors: An analysis of FDA-approved drugs. Drug Discovery Today, 2015 21(1), 5-10.
14. Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9(7), 463-475.
15. Hudis, C. A. Trastuzumab—mechanism of action and use in clinical practice. New England Journal of Medicine, 2007, 357(1), 39-51.
16. Scott, A. M, Wolchok J. D. & Old, L. J. Antibody therapy of cancer . Nature Reviews Cancer, 2012,12(4), 278-287.
17. Bondeson, D. P., Mares, A., Smith, I. E. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology, 2015, 11(8), 611-617.
18. Churcher, I. PROTACs: A paradigm shift in small molecule drug discovery. RSC Medicinal Chemistry, 2018, 9(1), 72-78.
19. Burslem, G. M., & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell, 2020 181(1), 102-114.
20. Cohen, P., & Alessi, D. R. Kinase drug discovery—what's next in the field? Nature Reviews Drug Discovery, 2013, 12(1), 61-69.
21. Knight, Z. A., & Shokat, K. M. Features of selective kinase inhibitors. Chemical Biology, 2005, 12(6), 621-637.
22. Roskoski. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Research, 2016, 103, 26-48.

23. Zhang, J., Yang, P. L., & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 2009, 9(1), 28-39.
24. Wu, P., Nielsen, T. E., & Clausen, M. H. Small-molecule kinase inhibitors: An analysis of FDA-approved drugs. Drug Discovery Today, 2015, 21(1), 5-10.
25. Garuti, L., Roberti, M., & Bottegoni, G. Non-ATP competitive protein kinase inhibitors. Current Medicinal Chemistry, 2011,18(20), 2981-2994.
26. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology, 2011, 29(11), 1039-1045.
27. Sharma, S. V., & Settleman, J. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes & Development, 2007, 21(24), 3214-3231.Sun, C., & Bernards, R. Feedback and redundancy in receptor tyrosine kinase signaling: Relevance to cancer therapies. Trends in Biochemical Sciences, 2014, 39(10), 465-474.
28. Wylie, A. A., Schoepfer, J., Jahnke, W. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 2017, 543(7647), 733-737.
29. Ferguson, F. M., & Gray, N. S. Kinase inhibitors: The road ahead. Nature Reviews Drug Discovery, 17(5), 353-377.
30. Yap, T. A., Omlin, A., & de Bono, J. S. Development of therapeutic combinations targeting major cancer signaling pathways. Journal of Clinical Oncology, 2017, 31(12), 1592-1605.
31. Lavoie, H., & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nature Reviews Molecular Cell Biology, 2015, 16(5), 281-298.
32. Deeks, E. D. Ripretinib: First approval. Drugs, 2020, 80(10), 1133-1138.
33. Mayer, T. U. Challenges in kinase inhibitor development: Target selection, specificity, and resistance mechanisms. Trends in Pharmacological Sciences, 2020, 41(4), 227-229.
34. Gorre, M. E., Mohammed, M., & Ellwood, K. BCR-ABL kinase mutations and imatinib resistance in chronic myelogenous leukemia. Nature, 2001, 411(6835), 215-218.
35. Basak, S., & Ghosh, A. Pharmacokinetics and pharmacodynamics of kinase inhibitors: An overview of the current generation. Frontiers in Pharmacology, 2015, 6, 118.
36. Lu, Y., & Zhang, X. The pharmacokinetics and pharmacodynamics of small-molecule kinase inhibitors. Drug Development Research, 2017, 78(4), 162-173.

37. Li, Y., & Lee, K. Kinase inhibitors: Pharmacokinetics and drug interactions. Pharmacological Research, 2017, 122, 11-20.
38. de Boer, J., & Boersma, L. Toxicity of kinase inhibitors: A clinical overview. Cancer Chemotherapy and Pharmacology, 2007, 59(4), 469-478.
39. Hwang, J. J., & Lee, J. W. Targeted cancer therapies: Understanding pharmacokinetics and toxicity. Journal of Clinical Pharmacology, 2019, 59(12), 1679-1687.
40. Gromov, P., & Gromova, I. Pharmacokinetics and pharmacodynamics of targeted therapies: Bridging the gap between preclinical and clinical stages. Cancer Treatment Reviews, 2020, 85, 101984.
41. Patel, A., & Sadiq, M. Adverse effects and toxicity profile of kinase inhibitors: An overview. European Journal of Pharmacology, 2020, 884, 173323.
42. Baumer, J. D., & Sadar, M. D. Pharmacokinetic and pharmacodynamic issues in kinase inhibitor development. Pharmacology & Therapeutics, 2016, 167, 106-119.
43. Al-Kassir, A., & Reimer, T. The impact of drug metabolism on kinase inhibitor therapy: Implications for treatment efficacy and safety. Clinical Cancer Research, 2014, 20(15), 3794-3803.
44. Zhang, J., Yang, P. L., & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 2009, 9(1), 28-39.
45. Fabbro, D., & Cowan-Jacob, S. W. Kinase inhibitors: A new era in cancer treatment. Biochemical Society Transactions, 2005, 33(6), 1065-1070.
46. Iwata, H., & Tokunaga, T. PROTACs: A promising approach for targeted protein degradation. Trends in Pharmacological Sciences, 2018, 39(3), 198-207.
47. Blacklock, J. M., & Kogiso, M. The potential of PROTACs for drug discovery. Drug Discovery Today, 2019, 24(5), 1060-1067.
48. Palmer, J. A., & Jain, A. Covalent inhibitors in cancer therapy. *Journal of* Medicinal Chemistry, 2020, 63(4), 1432-1445.
49. Wylie, A. A., Schoepfer, J., Jahnke, W. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 2017, 543(7647), 733-737.
50. Kumar, S., Saha, S., Singh, K., Singh, T., Mishra, A. K., Dubey, B. N., & Singh, S. (2024). Beneficial effects of spirulina on brain health: A systematic review. Current Functional Foods, 3(1), Article e120124225622. https://doi.org/10.2174/0126668629269256231222092721

51. RaviKKumar VR, Rathi S, Singh S, Patel B, Singh S, Chaturvedi K, Sharma B. A Comprehensive Review on Ulcer and Their Treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 21;39:e20230006. doi: 10.62958/j.cjap.2023.006. PMID: 38755116.
52. Singh, V., Arora, S., Akram, W., Alam, S., Kumari, L., Kumar, N., Kumar, B., Kumar, S., Agrawal, M., Singhal, M., Kumar, S., Singh, S., Singh, K., Saha, S., & Dwivedi, V. (2024). Involvement of molecular mechanism and biological activities of Pemirolast: A therapeutic review. New Emirates Medical Journal, 5, Article e02506882308410. https://doi.org/10.2174/0102506882308410240607053814
53. Rajput DS, Gupta N, Singh S, Sharma B. A Comprehensive Review: Personalized Medicine for Rare Disease Cancer Treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 23;39:e20230008. doi: 10.62958/j.cjap.2023.008. PMID: 38830754.
54. Singh S, Chaurasia A, Rajput DS, Gupta N. Mucoadhesive Drug Delivery System and There Future Prospective: Are a Promising Approach for Effective Treatment? Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 20;39:e20230005. doi: 10.62958/j.cjap.2023.005. PMID: 38751344.
55. Kumar, S., Saha, S., Sharma, B., Singh, S., Shukla, P., Mukherjee, S., Agrawal, M., Singh, K., & Singh, T. (2023). The role of resveratrol in Alzheimer's disease: A comprehensive review of current research. Current Functional Foods, 2(2), Article e121223224364, 13 pages. https://doi.org/10.2174/0126668629269244231127071411
56. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.
57. Vaghela MC, Rathi S, Shirole RL, Verma J, Shaheen, Panigrahi S, Singh S. Leveraging AI and Machine Learning in Six-Sigma Documentation for Pharmaceutical Quality Assurance. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jul 18;40:e20240005. doi: 10.62958/j.cjap.2024.005. PMID: 39019923.
58. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications.

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.

59. Kumar, S., Saha, S., Pathak, D., Singh, T., Kumar, A., Singh, K., Mishra, A. K., Singh, S., & Singh, S. (2024). Cholesterol absorption inhibition by some nutraceuticals. Recent Advances in Food, Nutrition & Agriculture, 16(1), 2–11. https://doi.org/10.2174/012772574X285280240220065812
60. Singh, S., Chaurasia, A., Rajput, D. S., & Gupta, N. (2024). An overview on mucoadhesive buccal drug delivery systems & approaches: A comprehensive review. African Journal of Biological Sciences (South Africa), 6(5), 522–541, DOI: 10.33472/AFJBS.6.5.2024.522-541
61. Kumar, S., Singh, S., Rajput, D., Sharma, B., Chaturvedi, K., Singh, N., Saha, S., Singh, K., & Mukherjee, S. (2024). Pharmacological approaches and herbal interventions for Alzheimer's disease. The Natural Products Journal, 14(8), Article e220124225945. https://doi.org/10.2174/0122103155275266231123090138
62. Ravikkumar VR, Patel BD, Rathi S, Parthiban S, Upadhye MC, Shah AM, Rehan SSA, Samanta S, Singh S. Formulation and Evaluation of Drumstick Leaves Tablet as An Immunomodulator. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 21;40:e20240004. doi: 10.62958/j.cjap.2024.004. PMID: 38902996.
63. Sharma, A., Bara, G., Keshamma, E., Sharma, B., Singh, S., Singh, S. P., Parashar, T., Rathore, H. S., Sarma, S. K., & Rawat, S. (2023). Cancer biology and therapeutics: A contemporary review. Journal of Cardiovascular Disease Research, 14(10), 1229-1247.
64. Dewangan, H. K., Singh, S., Mishra, R., & Dubey, R. K. (2020). A review on application of nanoadjuvant as delivery system. International Journal of Applied Pharmaceutics, 12(4), 24–33. https://doi.org/10.22159/ijap.2020v12i4.36856
65. Singh S, Chaurasia A, Gupta N, Rajput DS. Effect of Formulation Parameters on Enalapril Maleate Mucoadhesive Buccal Tablet Using Quality by Design (QbD) Approach. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 27;40:e20240003. doi: 10.62958/j.cjap.2024.003. PMID: 38925868.
66. Zhi, L., & Lee, P. Mechanisms of resistance to kinase inhibitors. *Nature* Reviews Drug Discovery, 2020, 19(9), 1-17.
67. Tong, Z., & Zhang, L. Overcoming resistance to kinase inhibitors: Emerging strategies. Journal of Hematology & Oncology, 2018, 11(1), 1-13.

68. Lu, Y., & Zhang, X. The pharmacokinetics and pharmacodynamics of small-molecule kinase inhibitors. Drug Development Research, 2017, 78(4), 162-173.
69. Shi, T., & Li, G. Structure-based design of selective kinase inhibitors. Trends in Pharmacological Sciences, 2017, 38(4), 346-357.
70. Holohan, C., & Van Schaeybroeck, S. Cancer therapy: Targeting the epidermal growth factor receptor. Cancer Therapy, 2014, 9(2), 215-223.
71. Vascular endothelial growth factor receptor inhibitors: Development and clinical applications in cancer. Cancer Research and Therapy, 2016, 72(11), 2132-2141.
72. Eder, J., & Rojas, B. Clinical applications of BRAF inhibitors in the treatment of melanoma. Journal of Clinical Oncology, 2017, 35(3), 318-328.